SLNO Patricia C Hirano sells $265K worth of shares
Apr 03, 2025, 4:35 AM
0.00%
What does SLNO do
Soleno Therapeutics, a clinical-stage biopharmaceutical company based in Redwood City, California, focuses on developing novel therapeutics for rare diseases, notably DCCR for Prader-Willi syndrome. DCCR, a once-daily oral tablet, recently completed Phase 3 trials and has received Fast-Track and orphan designations in the U.S. and EU.
Patricia C Hirano sold 3,782 shares of SLNO on 1 April at $70.11 per share, worth a total of $265K. They now own 27,036 SLNO shares, or a 12% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
